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Abstract: Background: Hepatitis
B Virus (HBV) infection has
reached pandemic proportions all
over the world with areas of high-
est prevalence being the sub-
Saharan Africa and Southeast
Asia. Most deaths related to HBV
are due to complications from
chronic infection. Acquisition of
infection at a younger age is the
most important predictor of
chronicity. Eradication of HBV is
an important but difficult tasks
facing public health. HB immuni-
zation is the single most important
factor in hepatitis B control and
was commenced in 2004 in
Nigeria.
Objectives: To determine the
prevalence of Hepatitis B surface
antigen (HBsAg) among children
in the era of HB immunization,
the risk factors of transmission
and knowledge of mothers about
their HB status.
Methods: A cross sectional study
carried out on one hundred and
forty children aged 18 months to
15 years at the children outpatient
clinic (CHOP) of the University
of Nigeria Teaching Hospital,
Ituku. Hepatitis B surface antigen
(HBsAg) was determined using
Determine Test Kits and a struc-
tured interviewer administered
questionnaire administered.
Results: Six were positive for
HBsAg, giving a prevalence rate
of 4.3%. HBsAg was least preva-
lent among children 1-5 years
(2%). None of the children ≤ 5
years who received HB vaccina-
tion was positive for HBsAg
though one child > 5 years who
received the vaccine was positive.
Sharing of toothbrushes among
siblings was found to be a signifi-
cantly associated risk factor. Only
6.4% of mothers knew their hepa-
titis B status.
Conclusion: There is a gradual fall
in the prevalence of HBsAg in our
environment due to HB immuniza-
tion. Sharing of toothbrushes may






Hepatitis B Virus (HBV) is a ubiquitous partially double
stranded DNA virus with areas of  highest prevalence
being the sub-Saharan Africa, South-East Asia, the
Amazon basin, Alaska, Northern Canada, Eastern
Europe, Greenland, parts of the Middle East, China, and
parts of Pacific Islands1. The infectious virus consists of
an outer envelope – HBsAg, the first seromarker and
one of the most useful markers of active or chronic
hepatitis B infection, and an inner core made up of
Hepatitis B core Antigen (HBcAg), found in acute or
chronic infections and the e-antigen (HBeAg), which
serves as a marker of active viral replication2,3,4,5. An
estimated 2 billion people have been infected with HBV,
with 350-400 million of them remaining chronic carriers
worldwide6,7. It has also been estimated that 25 - 30% of
the chronic carriers will die of the sequelae8,9. In Africa,
the number of HBV carriers is estimated to be about 50
million representing about 10-20% of the general popu-
lation and as many as 12.5 million will eventually die
due to complications from hepatitis B – chronic  hepati-
tis, cirrhosis and hepatocellular carcinoma (HCC)8,9.
Annual mortality directly related to hepatitis B liver
disease and cancer worldwide has been between 600,000
-1 million1.
Younger age at acquisition of infection continues to be
the most important predictor of chronic carriage and
those who develop chronic hepatitis B have a 15 - 40 %
risk of developing the complications4,6 this chronicity
being due to their immature immune system. More than
95% of adults spontaneously recover from an acute
HBV infection as defined by clearance of the HBsAg
from the blood, an effect that reflects the host’s degree
of immune response4,10. Transmission occurs when in-
fected blood or body fluid from an infected person en-
ters the body of another who is not immune1,11. Africans
who are carriers of HBV are infected in early childhood,
predominantly by horizontal transmission8,9. Vertical
transmission contributes 5-15% - (occurring more in
those with high viral load and actively replicating virus)
8. However, for unknown reasons, probably genetic,
HBeAg positivity rates are much lower in African
women of childbearing age8,9.
The eradication of HBV is one of the most important but
difficult tasks facing public health in Nigeria. This
maybe due to ignorance, about the infectivity (including
mechanisms of transmission) and the dire consequences
of HBV infection in children. This most probably, being
because the infections are asymptomatic and the
sequalae are long. It may also be from the poor immuni-
zation coverage in Nigeria. As at 2010, the national im-
munization coverage was 69% using DPT3 coverage
12.
There are three major methods of controlling HBV in-
fection. The first is   immunization, which is the single
most important factor in hepatitis B control, has the po-
tential of eradicating hepatitis B and studies have con-
firmed protection following vaccination in both industri-
alized and non-industrialized communities7,8,13. It’s in-
corporation into National immunization programme is
designed to reduce the risk of early childhood acquisi-
tion of HBV thereby reducing the number of chronic
carriers in endemic populations and has the advantage of
accessing infants through pre-existing vaccine delivery
systems and vaccinating individuals prior to their engag-
ing in high risk behaviours14,15. Next is the use of antivi-
ral drugs such as lamivudine, tenofovir, ribavirin etc.
Then the immunostimulatory therapy with α-interferon
and pegylated α-interferon7. Other adjuncts include con-
tinued screening of pregnant mothers for HBsAg to pre-
vent vertical transmission,  post exposure prophylaxis
using hyperimmune globin within 24 hours or at most 7
days following exposure14, and massive and sustained
public health education on the various avoidable modes
of transmission of HBV and available preventive meas-
ures.
The universal HB immunization was commenced in
Nigeria in 2004 as other major modalities are almost
nonexistent. Hence mass vaccination in a large scale
ought to become imperative as this will decrease the
reservoir of chronic carriers. HB immunization coverage
in Nigeria in 2010 was 66%12. Some previous studies
between 1983-2005 have reported prevalence rates of
6.5-7.6% in Enugu and the environs when HB immuni-
zation was nonexistent16,17,18. This study was therefore
undertaken to determine the prevalence of HBsAg
among children in this era of HB immunization, the
remote risk factors of HBV transmission in our environ-
ment and knowledge of mothers about their HB status.
Methods
The study was carried out at the Children Outpatient
clinic of the University of Nigeria Teaching Hospital, a
tertiary medical institution in Enugu. It was cross sec-
tional, recruiting consecutively 140 children who at-
tended the clinic with minor illnesses such as upper res-
piratory tract infections, malaria etc. from July to De-
cember 2010. Inclusion criteria were ages 18 months to
15 years and those whose parent (s) gave informed con-
sent while all children less than 18 months or above 15
years of age as well as those whose parents refused to
consent despite due education on the need for the study
were excluded.
Ethical clearance was obtained from the University of
Nigeria Teaching Hospital Health Research and Ethics
committee. Informed consent – both verbal and written,
were obtained from the child and/or the parent (s). They
were duly educated on the need for, and benefits of the
study, the specimen to be collected and how it was to be
collected. A structured interviewer administered ques-
tionnaire was designed for the study. Information sought
included biodata, occupational and educational status of
both parents – for the determination of socioeconomic
class, risk factors for HBV infection including previous
history of blood transfusion, history of scarification,
tattooing, ear piercing, circumcision, use of contami-
nated needles and syringes for injection (either used or
reused needle or syringe was considered as contami-
nated), intravenous drug use, histories of sex (where
necessary), bites by other children, and sharing of tooth
brush. Others were child immunization status and
knowledge of maternal immunization status. The immu-
nization cards of all those who received the vaccine
were demanded and verified.
Assay for HBsAg was done using Abbott Determine
HBsAg test kits - an enzyme immunoassay (specificity
of 99.85% and a sensitivity of 94.64%). The test was
then read after a waiting interval of 15 minutes to 24
hours (as specified by the manufacturer).
The data were analyzed using SPSS version 19. Meas-
ures of central tendency – the mean were used to sum-
marize quantitative variables where applicable. Fre-
quency tables were constructed as appropriate. Chi
square analysis for non-continuous variables with p
value at the level of < 0.05 as significant was also done.
Odds ratios for the risk factors were calculated. Socio-
economic class was determined using the method pro-
posed by Oyedeji.19
Results
The age and sex distribution of the study population is
as shown in Table 1. The mean age of the children was
7.27 ± 3.6 years. There were 74 males and 66 females
with a male to female ratio of 1.1: 1. The majority of the
children 62 [44.3%] were in the age range of 6-10 years.
The least represented age range was 11-15 years – 28
(20%).Their socioeconomic class is also as shown in
Table 1. Most of the subjects were in the lower class.
Among the 140 children, 6 were positive for HBsAg,
giving a prevalence rate of 4.3%.  Of the 6 HBsAg posi-
tive children, 5 belonged to the lower socioeconomic
class while one belonged to the middle class.  Three of
the males and 3 of the females were positive for HBsAg
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giving a prevalence rate of 4.1% and 4.5% respectively.
The observed differences in the prevalence rates be-
tween males and females were not of statistical signifi-
cance. The least prevalence was also observed among
children 1-5 years (2%) while the highest prevalence of
HBsAg was observed among those aged 6-10 years
(6.5%) [C2 = 1.4 –X2 =1.4, p = 0.5]. Table 2.
Table 1: Socio-demographic characteristics of the study
subjects
* The lowest age in this study was 18 months
Table 2: Showing age prevalence of HBsAg
Among the 50 children who were 5 years or less, 45
(90%) received HB immunization while the remaining 5
(10%) could not recall whether or not they received the
vaccine. Thirty six (40%) children out of the 90 who
were more than 5 years old received the immunization,
25 (27.8%) said they did not receive the immunization,
29 (32.2%) could not recall receiving the immunization.
None of the children ≤ 5 years who had received HB
immunization was positive for HBsAg. However, one
(2.8%) child > 5 years who claimed (immunization not
verified as subject has no card) to have received HB
immunization was HBsAg positive. Table 3.
Among the children studied, whether HBsAg positive or
negative, none was involved with intravenous drug
abuse or unprotected sex. However, all had received
intramuscular injections for one reason or the other as is
depicted in Table 4.
Fifteen (10.7%), used contaminated needle/syringe. Sev-
enteen (12.1%) had a past history of blood transfusion,
20 (14.3%) had scarification marks, 1(0.7%) had a tat-
too, 75 (53.6%) were circumcised, 63 (45%) had ear
piercing, 37 (26.4%) shared toothbrushes at one time or
the other with other siblings (C2 = 5.22 -X
2 =5.22, p =
0.04) and 55 (39.3%) had been bitten by other children
at one time or the other. However, the odds ratio of the
risk of transmission of HBV through these risk factors is
as shown in table 4.
Among the mothers of these children, only nine (6.4%)
knew their hepatitis B status. Of these seven were nega-
tive for HBsAg while 2 were positive. None of the chil-








Upper class 31 (22.1)
Middle class 43 (30.7)









1-5 1 (2.0) 49 (98.0)
6-10 4 (6.5) 58 (93.5)
11-15 1 (3.6) 27 (96.4)
dren of the positive mothers were positive for HBsAg.
Table 3: Showing the distribution of HBsAg among
immunized children
Table 4: Risk factors of HBV and their relative risk of
positivity among the subjects
Discussion
This study has demonstrated an HBsAg prevalence rate
of 4.3%. This is lower than the 6.6% recorded in this
center five years earlier16. It therefore demonstrates the
gradual fall in HBsAg prevalence among children in our
environment as a result of HB immunization. It is also
lower than the 7.6% reported by Chukwuka et al17 in
Nnewi and 10.7% recorded by Jibrin, et al2 in Sokoto at
the same time as this study. Earlier studies have also
documented higher prevalence of HBV in Northern Ni-
geria than Enugu – 9.4% by Ashir, et al,2 044.7% by
Bukbuk et al21. This reduction in HBsAg rates call for
strengthening of routine immunization and sustained
efforts in all parts of Nigeria, to reduce significantly the
hyperendemicity of HBV.
The highest prevalence of HBsAg positivity was found












≤ 5 45 0 (0.0) 45 (100.0)










Present 17 1 (5.9) 0.12 0.55 1.5
Absent 123 5 (4.1)
Scarification mark
Present 20 2 (10.0) 1.86 0.20 3.2
Absent 120 4 (3.3)
Tattooing
Present 1 0 (0.0) - - -
Absent 139 6 (4.3)
Circumcision
Present 75 3 (4.0) 0.04 1.00 0.9
Absent 65 3 (4.6)
Intravenous drug use
Absent 140 6 (4.3) - - -
Contaminated syringe/needle
Present 15 0 (0.0) - - -
Absent 125 6 (4.8)
Present 63 3 (4.8) 0.06 1.00 1.2
Absent 77 3 (3.9)
Sharing of toothbrush
Present 37 4 (10.8) 5.22 0.04 6.1
Absent 103 2 (1.9)
Bitten by playmates
Present 55 4 (7.3) 2.04 0.21 0.3
Absent 85 2 (2.4)
Unprotected sex
Absent 140 6 (4.3) - - -
Ear piercing
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of HBsAg positivity in this age group agrees with other
studies in Enugu.16,18This may be because at this age
most children are very active and exploring their world.
However, it differs with the observations by Jibrin2and
Alikor22 who found highest prevalence rate among chil-
dren 11-15 years. The difference in age group of preva-
lence may be because of increase in other high risk be-
haviors including unprotected sexual habits among chil-
dren of this age group, Port Harcourt being a seaport and
more cosmopolitan. Komas, et al23had noted higher
prevalence of HBV markers among adolescents and
young adults in Bangui, who did not use condom and
also those having more than one sexual partner. It may
also be as a result of the inability of these children to
lose the surface antigen due to impaired immunity.
In this study, zero prevalence was observed in the age
group 18 months -3 years, which may imply that vertical
transmission of HBV has remained low in Nigerian
women. This prevalence rate in this age group may fur-
ther highlight the effectiveness of HB vaccine in an en-
demic area like ours. Considering that Emechebe16docu-
mented a prevalence rate of 5.6% among children 2-5
years in this centre 5 years earlier, this study’s 2%
among same age range may be due to vaccine efficacy.
An increasing prevalence of HBsAg with age was also
observed in this study. Other studies have also noted a
similar trend.2,16,22 This pattern still shows the predomi-
nance of horizontal transmission of HBV infection in
our environment. A slightly higher prevalence of
HBsAg was observed among the females. Though the
prevalence rates observed in this study are lower, it is at
variance with the finding in Enugu earlier,16 in Port Har-
court22 and in Borno21 who observed a higher prevalence
among males.
The social class of the parents in this study was not sig-
nificantly associated with HBsAg positivity. This may
be because of equal exposure to the risk factors of HBV
among children of different social classes. However, in
this study it was observed that the higher the social
class, the lower the number of children positive to
HBsAg. This could be because people in the lower so-
cioeconomic class are more likely to indulge in activities
that may promote infection with HBV such as alterna-
tive medicine, share sharp objects and toothbrushes.
This is similar to the findings of Komas,23 and
Emechebe.16
In 2004, the universal HB immunization was com-
menced in Nigeria though it was incorporated into the
National Programme of Immunization (NPI) in 1995.
The total sum of vaccinated children in this study who
were sure of their immunization was 81. Only one was
positive for surface antigen. If actually this subject re-
ceived complete doses of the vaccine, it may point to the
fact that it is not 100% effective in preventing HBV in-
fection. This prevalence of 1.2% is comparable to that
observed by Odusanya, et al.13 Not minding this find-
ing, with such a level of vaccine efficacy it is likely to
impact positively and prevent or reduce the transmission
of hepatitis B infection in the community.
This study also revealed a very poor knowledge of hepa-
titis B among the mothers. That only 6.4% knew their
HB status is worrying and reflects the poor general
knowledge and attitude towards hepatitis B. The impli-
cation is the hyperendemicity of this deadly disease in
Nigeria. This calls for massive public health enlighten-
ment campaign just like in HIV/AIDS to curb this dis-
ease. In developing countries like Nigeria, intravenous
drug use is not yet common among children. However,
exposure to repeated injections sometimes with contami-
nated therapeutic injection equipment, probably due to
ignorance, parental preferences, or lack of awareness of
infection control practices and resources for sterilization,
are very common.24The zero prevalence in this study
among the risk factors of tattooing and contaminated
needle/syringe may have been as a result of the small
sample size involved.  Also although not statistically
significant as risk factors, but as has been documented
previously blood transfusion and scarification marks
have odd ratios of 1.5 and 3.2 respectively, making them
potent risk factors. 24 Al-Fawaz25had adduced that even
an HBsAg free blood obtained by the very sensitive 3rd
generation screening techniques can not completely
safeguard against HBV. This is true of occult hepatitis B
in which there is presence of HBV DNA in the liver in
the absence or undetectable serum HBsAg and measur-
able or immeasurable serum HBV DNA.26Also, it had
been noted that history of blood transfusion was a suffi-
cient risk factor for chronic hepatitis B infection, a ma-
jor etiologic factor for primary hepatocellular carcinoma
in Africa.27
Sharing of toothbrush among siblings/household mem-
bers was found to be statistically significant while bite
by playmates was not. The alkaline nature of the saliva
may have been contributory in hindering transmission
through bite. However, an intraoral trauma during
brushing could be the source of transmission. Also the
chance of transmitting the virus through this route is
likely to be substantial given the fact that such sharing is
likely to occur over prolonged periods. This finding is
similar to that by Nwokediuko.24
Conclusion
There is a gradual fall in the prevalence of hepatitis B
surface antigen in our environment possibly due to HB
immunization. The vaccine may also not be 100% pro-
tective. Sharing of toothbrush was found to be a signifi-
cantly associated mode of transmission of HBV infec-
tion. There is a very poor knowledge of HBV among our
people.
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